© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90589 refers to the chikungunya virus vaccine, which is a live attenuated vaccine intended for intramuscular use. Vaccines are biological preparations that provide active, long-term immunity by introducing a modified version of a virus into the body. This process stimulates the immune system to recognize the virus and produce specific antibodies that can combat future infections. The chikungunya virus is transmitted through the bites of infected mosquitoes and is associated with symptoms such as fever, severe joint and muscle pain, fatigue, headache, and occasionally a rash. The vaccine described by this code contains a weakened form of the chikungunya virus, which is incapable of causing the disease but is still effective in prompting the immune system to respond. It is important to note that this code specifically pertains to the vaccine product itself and does not encompass the administration of the vaccine, which would be reported separately. This distinction is crucial for accurate medical coding and billing practices.
© Copyright 2025 Coding Ahead. All rights reserved.
The chikungunya virus vaccine is indicated for individuals who are at risk of contracting the chikungunya virus, particularly those living in or traveling to areas where the virus is prevalent. The vaccine is designed to provide protection against the chikungunya virus, which can lead to significant morbidity due to its associated symptoms, including fever, joint pain, muscle pain, fatigue, headache, and rash.
The administration of the chikungunya virus vaccine involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine. First, the healthcare provider must verify the patient's eligibility for vaccination, including assessing any contraindications or previous allergic reactions to vaccines. Next, the provider prepares the vaccine by ensuring it is stored correctly and is at the appropriate temperature for administration. The vaccine is then drawn into a syringe, taking care to avoid contamination. Following this, the provider selects an appropriate site for intramuscular injection, typically the deltoid muscle in the upper arm for adults. The skin at the injection site is cleaned with an antiseptic to minimize the risk of infection. The vaccine is then injected into the muscle, and the provider may apply gentle pressure to the site afterward. Finally, the patient is monitored for a brief period post-injection to observe for any immediate adverse reactions.
After the administration of the chikungunya virus vaccine, patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate side effects or allergic reactions. Common post-vaccination reactions may include mild pain or swelling at the injection site, low-grade fever, or fatigue. Patients should be informed about these potential side effects and advised to report any unusual or severe reactions. Additionally, it is important for patients to receive information regarding follow-up vaccinations if required and to maintain a record of their vaccination status for future reference. Overall, the expected recovery time is minimal, and most individuals can resume normal activities shortly after vaccination.
| Short Descr | CHIKUNGUNYA VACCINE LIVE IM | Medium Descr | CHIKUNGUNYA VIRUS VACCINE LIVE FOR IM USE | Long Descr | Chikungunya virus vaccine, live attenuated, for intramuscular use | Status Code | Non-Covered Service | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-01-01 | Added | Code added. |
| 2023-11-09 | Changed | FDA approval granted |
Get instant expert-level medical coding assistance.